Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.63 USD
Change Today 0.00 / 0.00%
Volume 0.0
PURE On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

pure bioscience inc (PURE) Snapshot

Open
$0.63
Previous Close
$0.63
Day High
$0.63
Day Low
$0.63
52 Week High
10/20/14 - $1.22
52 Week Low
05/8/15 - $0.34
Market Cap
25.9M
Average Volume 10 Days
19.2K
EPS TTM
$-0.21
Shares Outstanding
41.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PURE BIOSCIENCE INC (PURE)

Related News

No related news articles were found.

pure bioscience inc (PURE) Related Businessweek News

No Related Businessweek News Found

pure bioscience inc (PURE) Details

Pure Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States. It manufactures and distributes silver dihydrogen citrate based disinfecting and sanitizing products. The company’s technology platform is based on an electrochemical process that allows generating ionized silver in the presence of organic acid. It provides PURE Hard Surface, a hard surface disinfectant and food contact surface sanitizer for use in food processing equipment, machinery, and utensils; PURE Multi-Purpose Cleaner, an environmentally cleaning product for use in various resilient surfaces, such as floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate, an environmentally high foam forming cleaning product for use in stainless steel equipment, resilient floors, walls, and painted surfaces. The company also offers Axen 30, a hard surface disinfectant; Axenohl, an antimicrobial formulation used as a raw material in the manufacturing of environmental protection agency-registered products; and Silvérion, an antimicrobial formulation used as a raw material in the manufacturing of personal care products. Pure Bioscience, Inc. markets and sells its products primarily to distributors and end users. The company was formerly known as Pure Bioscience and changed its name to Pure Bioscience, Inc. in March 2011. Pure Bioscience, Inc. was founded in 1992 and is based in El Cajon, California.

12 Employees
Last Reported Date: 01/12/15
Founded in 1992

pure bioscience inc (PURE) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $406.5K
Compensation as of Fiscal Year 2014.

pure bioscience inc (PURE) Key Developments

PURE Bioscience, Inc. Announces Executive Changes

PURE Bioscience, Inc. announced the resignation of Peter C. Wulff as its Chief Financial Officer and Chief Operating Officer. Wulff informed the Company that he has accepted a new assignment as CFO for a venture-backed medical device company. With Wulff's departure, Mark Elliott, PURE's Controller, has been promoted and will play a new leadership role in PURE's Finance department as the Company's Vice President, Finance and will serve as the Company's principal financial and accounting officer. Elliott joined PURE in 2004 and has been responsible for managing all accounting and regulatory reporting activities since May 2006. He has also been responsible for establishing all current financial and reporting systems. Prior to joining PURE, Elliott worked in government accounting.

PURE Bioscience, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and First Nine Months Ended April 30, 2015

PURE Bioscience, Inc. announced unaudited consolidated earnings results for the third quarter and first nine months ended April 30, 2015. For the quarter, the company announced net product sales of $109,000 compared to $261,000 for the same period a year ago. Loss from operations was $2,100,000 compared to $2,184,000 for the same period a year ago. Net loss was $2,091,000 compared to $2,049,000 for the same period a year ago. Basic and diluted net loss per share was $0.05 compared to $0.07 for the same period a year ago. Net loss, as adjusted for significant items was $1,325,000 compared to $1,279,000 for the same period a year ago. Operating cash for the fiscal third quarter 2015 was $1.4 million. For the first nine months, the company announced net product sales of $499,000 compared to $417,000 for the same period a year ago. Loss from operations was $5,766,000 compared to $9,237,000 for the same period a year ago. Net loss was $5,761,000 compared to $8,375,000 for the same period a year ago. Basic and diluted net loss per share was $0.15 compared to $0.34 for the same period a year ago. Net loss, as adjusted for significant items was $4,010,000 compared to $3,849,000 for the same period a year ago.

PURE Bioscience, Inc. Presents at Impact Investor Conference, Jun-19-2015 10:30 AM

PURE Bioscience, Inc. Presents at Impact Investor Conference, Jun-19-2015 10:30 AM. Venue: Minneapolis Club, 729 2nd Ave S, Minneapolis, MN 55402, United States. Speakers: Hank R. Lambert, CEO.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PURE:US $0.63 USD 0.00

PURE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PURE.
View Industry Companies
 

Industry Analysis

PURE

Industry Average

Valuation PURE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.7x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PURE BIOSCIENCE INC, please visit www.purebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.